Abstract:Background: Acute myeloid leukemia (AML) is the most common form of leukemia among adults and is characterized by uncontrolled proliferation and clonal expansion of hematopoietic cells. There has been a significant improvement in the treatment of younger patients, however, prognosis in the elderly AML patients remains poor. Methods: We used computational methods and machine learning (ML) techniques to identify and explore the differential high-risk genes (DHRGs) in AML. The DHRGs were explored through multiple in silico approaches including genomic and functional analysis, survival analysis, immune infiltration, miRNA co-expression and stemness features analyses to reveal their prognostic importance in AML. Furthermore, using different ML algorithms, prognostic models were constructed and validated using the DHRGs. At the end molecular docking studies were performed to identify potential drug candidates targeting the selected DHRGs. Results: We identified a total of 80 DHRGs by comparing the differentially expressed genes derived between AML patients and normal controls and high-risk AML genes identified by Cox regression. Genetic and epigenetic alteration analyses of the DHRGs revealed a significant association of their copy number variations and methylation status with overall survival (OS) of AML patients. Out of the 137 models constructed using different ML algorithms, the combination of Ridge and plsRcox maintained the highest mean C-index and was used to build the final model. When AML patients were classified into low- and high-risk groups based on DHRGs, the low-risk group had significantly longer OS in the AML training and validation cohorts. Furthermore, immune infiltration, miRNA coexpression, stemness feature and hallmark pathway analyses revealed significant differences in the prognosis of the low- and high-risk AML groups. Drug sensitivity and molecular docking studies revealed top 5 drugs, including carboplatin and austocystin-D that may significantly affect the DHRGs in AML. Conclusion: The findings from the current study identified a set of high-risk genes that may be used as prognostic and therapeutic markers for AML patients. In addition, significant use of the ML algorithms in constructing and validating the prognostic models in AML was demonstrated. Although our study used extensive bioinformatics and machine learning methods to identify the hub genes in AML, their experimental validations using knock-out/-in methods would strengthen our findings.

Prediction of myeloid malignant cells in Fanconi anemia using machine learning

Identifying an AML Prognostic Model Using 10 Marker Genes from Single-Cell Transcriptome and Bulk Transcriptome Analysis

Mutation Spectrum, Expression Profiling, and Prognosis Evaluation of Fanconi Anemia Signaling Pathway Genes for 4259 Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia

Polyclonal Evolution of Fanconi Anemia to MDS and AML Revealed at Single Cell Resolution.

Comparing machine learning models for predicting mutation status in Acute Myeloid Leukemia patients using RNA-seq data

Survival prediction in acute myeloid leukemia using gene expression profiling

Proteomic Profiling and Bioinformatics Analysis Identify Key Regulators During the Process from Fanconi Anemia to Acute Myeloid Leukemia

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.

Predicting Molecular Alterations from Blast Morphology of Acute Myeloid Leukemia Bone Marrow Aspirate Smears Using Machine Learning

High temporal resolution prediction of mortality risk for single AML patient via deep learning

Differential diagnosis of bone marrow failure syndromes guided by machine learning

FANCA: In-Silico deleterious mutation analysis for early prediction of leukemia

Combining clinical and molecular data for personalized treatment in acute myeloid leukemia: A machine learning approach

Integrative Analysis of Gene Expression Data by RNA Sequencing for Differential Diagnosis of Acute Leukemia: Potential Application of Machine Learning

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

A Predictive Algorithm for Discriminating Myeloid Malignancies and Leukemoid Reactions

Construction and Validation of a Novel Ferroptosis-Related Prognostic Model for Acute Myeloid Leukemia

Identification of hub genes and potential molecular mechanisms related to drug sensitivity in acute myeloid leukemia based on machine learning

A Novel Fatty Acid Metabolism-Associated Risk Model for Prognosis Prediction in Acute Myeloid Leukaemia

Advanced Analysis and Validation of a microRNA Signature for Fanconi Anemia

Predicting RUNX1::RUNX1T1 genetic abnormalities in acute myeloid leukemia from bone marrow smears: Can artificial intelligence do better?